Correction to: Reduction in kidney function decline and risk of severe clinical events in agalsidase beta-treated Fabry disease patients: a matched analysis from the Fabry Registry.
修正：在接受 agalsidase beta 治療的 Fabry 病患者中，腎功能下降及嚴重臨床事件風險的減少：來自 Fabry 註冊的匹配分析。
Clin Kidney J 2024-10-18
Corrigendum to "WCN24-1105 PHARMACOGENETIC RISK FACTORS FOR TENOFOVIR-INDUCED KIDNEY TUBULAR DYSFUNCTION AMONG HIV-POSITIVE ADULT NIGERIANS" [<i>Kidney International Reports</i> Volume 9, Issue 4, Supplement, April 2024, Page S339].
對於「WCN24-1105 PHARMACOGENETIC RISK FACTORS FOR TENOFOVIR-INDUCED KIDNEY TUBULAR DYSFUNCTION AMONG HIV-POSITIVE ADULT NIGERIANS」的更正 [<i>Kidney International Reports</i> 第9卷，第4期，補充，2024年4月，第S339頁]。
Kidney Int Rep 2024-07-31
看起來你提到的是一篇有特定 DOI 的文章的更正。如果你需要幫助理解這個更正、總結文章內容，或是尋找更多相關資訊，請提供更多細節！
PubMedDOI
Corrigendum to "WCN24-1051 CLINICAL PROFILE, DIAGNOSIS, THERAPEUTIC INTERVENTION AND COMPLICATIONS IN RENAL BIOPSY IN CKD POPULATION - SINGLE CENTER 20 YEARS' EXPERIENCE" [<i>Kidney International Reports</i> Volume 9, Issue 4, Supplement, April 2024, Page S86].
對於「WCN24-1051 CLINICAL PROFILE, DIAGNOSIS, THERAPEUTIC INTERVENTION AND COMPLICATIONS IN RENAL BIOPSY IN CKD POPULATION - SINGLE CENTER 20 YEARS' EXPERIENCE」的更正 [<i>Kidney International Reports</i> 第9卷，第4期，補充，2024年4月，第S86頁]。
Kidney Int Rep 2024-07-31
Corrigendum to "The Association Between Metabolic Syndrome, Hyperfiltration, and Long-Term GFR Decline in the General Population" [<i>Kidney International Reports</i> Volume 8, Issue 9, September 2023, Pages 1831-1840].
對於「代謝症候群、高過濾率與一般人群長期GFR下降之間的關聯」的更正 [<i>Kidney International Reports</i> 第8卷，第9期，2023年9月，頁1831-1840]。
Kidney Int Rep 2024-07-31
Corrigendum to "WCN24-1267 EMPAGLIFLOZIN IMPROVES VITALITY AND PROTECT FROM ADVANCED GLYCATION END PRODUCTS IN ENDOTHELIAL CELLS" [<i>Kidney International Reports</i> Volume 9, Issue 4, Supplement, April 2024, Page S637].
對於「WCN24-1267 EMPAGLIFLOZIN 改善活力並保護內皮細胞免受高級糖化終產物的影響」的更正 [<i>Kidney International Reports</i> 第9卷，第4期，補充，2024年4月，第S637頁]。
Kidney Int Rep 2024-07-31
Corrigendum to "Analysis and Management of Rituximab Resistance in PLA2R1-Associated Membranous Nephropathy" [<i>Kidney International Reports</i> Volume 6, Issue 4, April 2021, Pages 1183-1188].
對於「Analysis and Management of Rituximab Resistance in PLA2R1-Associated Membranous Nephropathy」的更正 [<i>Kidney International Reports</i> 第6卷，第4期，2021年4月，頁1183-1188]。
Kidney Int Rep 2024-07-31
Reduction in kidney function decline and risk of severe clinical events in agalsidase beta-treated Fabry disease patients: a matched analysis from the Fabry Registry.
在接受 agalsidase beta 治療的 Fabry 病患者中，腎功能下降及嚴重臨床事件風險的減少：來自 Fabry 註冊的配對分析。
Clin Kidney J 2024-08-14
Corrigendum to "WCN24-2499 CAVEOLIN-1 AND CAVEOLIN-2 AS POTENTIAL URINARY EARLY BIOMARKERS OF RENAL INJURY IN ACUTE CHOLESTASIS IN RATS" [<i>Kidney International Reports</i> Volume 9, Issue 4, Supplement, April 2024, Page S541].
對於「WCN24-2499 CAVEOLIN-1 和 CAVEOLIN-2 作為急性膽汁淤積大鼠腎損傷的潛在尿液早期生物標記」的更正 [<i>Kidney International Reports</i> 第9卷，第4期，補充，2024年4月，第S541頁]。
Kidney Int Rep 2024-08-19